TY - JOUR
T1 - Supraventricular arrhythmias in patients with cardiac sarcoidosis
T2 - Prevalence, predictors, and clinical implications
AU - Viles-Gonzalez, Juan F.
AU - Pastori, Luciano
AU - Fischer, Avi
AU - Wisnivesky, Juan P.
AU - Goldman, Martin G.
AU - Mehta, Davendra
N1 - Funding Information:
Author contributions: Dr Viles-Gonzalez had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Dr Viles-Gonzalez: contributed to the study design, data analysis and interpretation, manuscript writing, and manuscript submission and revisions. Dr Pastori: contributed to the data collection and preparation of the manuscript. Dr Fischer: contributed to the manuscript writing and revision. Dr Wisnivesky: contributed to the statistical analysis and preparation of the manuscript. Dr Goldman: contributed to the echocardiographic data analysis and preparation of the manuscript. Dr Mehta: contributed to the study design, interpretation of the data, and revision of the manuscript. Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Wisnivesky is a member of the research board of EHE International and has received a grant from GlaxoSmithKline plc and a lecture honorarium from Novartis AG. Drs Viles-Gonzalez, Pastori, Fischer, Goldman, and Mehta have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2013/4
Y1 - 2013/4
N2 - Background: Cardiac sarcoidosis (CS) is known to be associated with congestive heart failure, conduction disorders, and tachyarrhythmias. Ventricular arrhythmias are the most feared cardiac manifestation because they often are unpredictable, may be the first manifestation of the disease, and may be fatal. The propensity for the development of supraventricular arrhythmias (SVAs) in patients with CS has not been described. The aim of this study was to assess the prevalence as well as the predictors of SVA. Methods: We retrospectively investigated 100 patients with biopsy specimen-proven systemic sarcoidosis and evidence of cardiac involvement (defined by cardiac biopsy specimen, PET scan, or cardiac MRI). The mean follow-up was 5.8 ± 3.6 years. ECG, Holter monitoring, implantable cardioverter defibrillator interrogations, or electrophysiology studies were used to document SVA. Echocardiographic data, demographics, and extracardiac involvement were recorded, and univariate and Poisson regressions were performed to compare characteristics of patients with and without documented SVA. Results: The prevalence of SVA was 32%, and atrial fibrillation was the most common arrhythmia, comprising 18% of the total burden, followed by atrial tachycardias (7%), atrial flutter (5%), and other supraventricular tachycardias (2%). Of the patients with SVA, 96% were symptomatic. Left atrial enlargement (LAE) was more frequent in the group with SVA, with an incidence of 267.8 per 1,000 person-years, and it significantly increased the likelihood of SVA on multivariate analysis (risk ratio, 6.12; 95% CI, 2.19-17.11). Diastolic dysfunction, systemic hypertension, and right atrial enlargement were predictors of SVA on univariate analysis. Left ventricular hypertrophy, right ventricular dysfunction, tricuspid valve disease, pulmonary hypertension, and pulmonary sarcoidosis were not associated with SVA on univariate analysis. Conclusions: The study systematically evaluated the frequency of SVA in a large number of patients with CS. SVA in patients with CS is frequent and associated with symptoms. LAE was clearly associated with the development of SVA in this patient population. The extent to which LAE predicts the occurrence of SVA in larger, more diverse CS populations should be evaluated prospectively.
AB - Background: Cardiac sarcoidosis (CS) is known to be associated with congestive heart failure, conduction disorders, and tachyarrhythmias. Ventricular arrhythmias are the most feared cardiac manifestation because they often are unpredictable, may be the first manifestation of the disease, and may be fatal. The propensity for the development of supraventricular arrhythmias (SVAs) in patients with CS has not been described. The aim of this study was to assess the prevalence as well as the predictors of SVA. Methods: We retrospectively investigated 100 patients with biopsy specimen-proven systemic sarcoidosis and evidence of cardiac involvement (defined by cardiac biopsy specimen, PET scan, or cardiac MRI). The mean follow-up was 5.8 ± 3.6 years. ECG, Holter monitoring, implantable cardioverter defibrillator interrogations, or electrophysiology studies were used to document SVA. Echocardiographic data, demographics, and extracardiac involvement were recorded, and univariate and Poisson regressions were performed to compare characteristics of patients with and without documented SVA. Results: The prevalence of SVA was 32%, and atrial fibrillation was the most common arrhythmia, comprising 18% of the total burden, followed by atrial tachycardias (7%), atrial flutter (5%), and other supraventricular tachycardias (2%). Of the patients with SVA, 96% were symptomatic. Left atrial enlargement (LAE) was more frequent in the group with SVA, with an incidence of 267.8 per 1,000 person-years, and it significantly increased the likelihood of SVA on multivariate analysis (risk ratio, 6.12; 95% CI, 2.19-17.11). Diastolic dysfunction, systemic hypertension, and right atrial enlargement were predictors of SVA on univariate analysis. Left ventricular hypertrophy, right ventricular dysfunction, tricuspid valve disease, pulmonary hypertension, and pulmonary sarcoidosis were not associated with SVA on univariate analysis. Conclusions: The study systematically evaluated the frequency of SVA in a large number of patients with CS. SVA in patients with CS is frequent and associated with symptoms. LAE was clearly associated with the development of SVA in this patient population. The extent to which LAE predicts the occurrence of SVA in larger, more diverse CS populations should be evaluated prospectively.
UR - http://www.scopus.com/inward/record.url?scp=84875966871&partnerID=8YFLogxK
U2 - 10.1378/chest.11-3214
DO - 10.1378/chest.11-3214
M3 - Article
AN - SCOPUS:84875966871
VL - 143
SP - 1085
EP - 1090
JO - Chest
JF - Chest
SN - 0012-3692
IS - 4
ER -